Optimization of antimalarials targeting multiple life stages of the parasite
针对寄生虫多个生命阶段的抗疟药物的优化
基本信息
- 批准号:10813425
- 负责人:
- 金额:$ 7.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-08-04 至 2026-07-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdsorptionAffectAntimalarialsApplications GrantsArtemisininsAzidesBenzofuransBiologicalBiological AssayBiological AvailabilityBloodCessation of lifeChemicalsChemistryChloroquineClinicalComplementConsensusContractsCopperDevelopmentDiazomethaneDiseaseDoseDrug KineticsDrug resistanceEscherichia coliEvolutionExcretory functionFundingGoalsGrowthHumanIn VitroInfectionLeadLibrariesLifeLigandsLiverMalariaMammalian CellMedicalMetabolismModificationMolecular TargetMusOralOral AdministrationParasite resistanceParasitesPharmaceutical PreparationsPhenotypePlasmaPlasmodiumPlasmodium bergheiPlasmodium falciparumPopulationPopulations at RiskPositioning AttributeProbabilityPropertyProteinsProteomicsRattusRecrudescencesResistanceResistance developmentRiskSeriesSolubilityStructureStructure-Activity RelationshipSynthesis ChemistryToxic effectTriageUnited States National Institutes of HealthWorkanalogasexualchemoproteomicschemotherapeutic agentdrug candidateexperimental studygenome sequencingimprovedin vivolead optimizationmalaria infectionmetermouse modelnovelnovel therapeuticsparent grantpathogenpharmacophorephotolysispre-clinicalpreclinical developmentpreventresistance mechanismscaffoldscreeningtimelinevirtualwhole genome
项目摘要
PROJECT SUMMARY/ABSTRACT [Parent grant]
The malaria parasite is one of the most deadly eukaryotic pathogens and more than 40% of the world's population is at risk
of contracting malaria. Due to growing resistance to currently available medications, there is a pressing medical need for
new drugs to prevent and treat malaria infection. This grant application focuses on the optimization of two novel
antimalarials (2a and (R)-3a) to target multiple life stages of the parasite that emerged from our previous work on the
Malaria Box compound MMV008138 that targets the apicoplast. These compounds were identified using a combination of
atomic property field-based virtual ligand screening (VLS) of a library of 5 million publicly available compounds and
synthetic chemistry campaigns. Although 2a and (R)-3a bear a structural resemblance to MMV008138 and kill asexual
blood-stages, their mechanism of action is independent of the apicoplast. In addition, whereas MMV008138 only affects
asexual blood-stages, 2a also kills Stage V gametocytes, and (R)-3a weakly kills Plasmodium berghei liver-stages. For each
of the two novel compound series, we will explore: i) structure activity relationships that control potency, cellular selectivity,
and efficacy; ii) structure property relationships that govern adsorption, distribution, metabolism, and excretion; and iii)
their potential mechanisms of action and resistance. The overarching goal of this project is to prioritize preclinical leads
having novel mechanism of action, high selectivity for Plasmodium versus the human host, and physicochemical properties
that are compatible with development of an orally available drug candidate. The two principal goals of this R01 proposal
are to: 1) structurally modify 2a (lead) and (R)-3a (hit) to optimize in vitro asexual blood-stage potencies in addition to
gametocitocydal and/or liver stage activities, drug-like properties, and pharmacokinetics, achieving in vivo P. berghei-
infected mice efficacy with a single oral dose ED90 ≤ 10 mg/kg for the 2a analogs (late lead) and an ED90 ≤ 40 mg/kg/day
with 1-3 oral doses for the (R)-3a series (early lead), and 2) identify the antimalarial mechanisms of action and resistance
of 2a and (R)-3a (or their more potent analogs) by chemoproteomic and resistance-selection approaches, respectively. The
ancillary goal of this proposal is to develop structure-activity relationships (SAR) for the P. falciparum gametocytocidal
potency and P. berghei liver-stage potency of these two series, and to determine consensus pharmacophores for multi-stage
activities (asexual blood-stage potencies plus gametocytocidal and/or liver-stage potencies). Efficacious compounds
identified in this way will thus be well-positioned for further preclinical development.
项目摘要/摘要(家长资助)
疟疾寄生虫是最致命的真核病原体之一,世界上40%以上的人口处于危险之中
感染疟疾的风险。由于对现有药物的抗药性日益增强,医学上迫切需要
预防和治疗疟疾感染的新药。这项拨款申请的重点是优化两部小说
抗疟药(2a和(R)-3a)靶向寄生虫的多个生命阶段,这些寄生虫是我们以前在
疟疾盒化合物MMV008138,靶向质外体。这些化合物是用一系列化合物组合鉴定的
基于原子属性场的虚拟配体筛选(VLS),该库包含500万个公开可用的化合物和
合成化学运动。尽管2a和(R)-3a在结构上与MMV008138相似,并杀死无性系
在血液期,它们的作用机制独立于质外体。此外,鉴于MMV008138仅影响
无性血阶段,2a也杀死V期配子细胞,而(R)-3a弱杀死伯氏疟原虫肝脏阶段。对于每个
在这两个新化合物系列中,我们将探索:i)控制效力、细胞选择性、
和功效;ii)支配吸附、分布、新陈代谢和排泄的结构性质关系;以及iii)
它们潜在的作用和抵抗机制。这个项目的首要目标是确定临床前线索的优先顺序。
具有新的作用机制、对疟原虫对人类宿主的高选择性和物理化学性质
与口服给药候选药物的开发相兼容。本R01提案的两个主要目标
目的是:1)对2a(铅)和(R)-3a(HIT)进行结构修饰,以优化体外无性血期潜力
配子细胞和/或肝脏阶段的活性、类药物特性和药代动力学,在体内实现了P.berghei-
2a类似物(晚期铅)单次口服ED90≤10 mg/kg和ED90≤40 mg/kg/d感染小鼠的疗效
口服1-3剂量的(R)-3a系列(早期铅),以及2)确定抗疟疾的作用机制和耐药性
2a和(R)-3a(或其更有效的类似物)分别通过化学蛋白质组学和抗性选择方法获得。这个
这项提议的辅助目标是发展恶性疟原虫杀配子细胞的结构-活性关系(SAR)。
这两个系列的效价和伯氏假单胞菌的肝期效价,并确定多阶段的共识药效团
活动(无性血液阶段潜力加上杀配子细胞和/或肝脏阶段潜力)。有效化合物
因此,以这种方式确定的药物将为进一步的临床前开发奠定良好的基础。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Malaria Box-Inspired Discovery of N-Aminoalkyl-β-carboline-3-carboxamides, a Novel Orally Active Class of Antimalarials.
疟疾盒启发发现 N-氨基烷基-β-咔啉-3-甲酰胺,一种新型口服活性抗疟药。
- DOI:10.1021/acsmedchemlett.1c00663
- 发表时间:2022
- 期刊:
- 影响因子:4.2
- 作者:Mathew,Jopaul;Ding,Sha;Kunz,KevinA;Stacy,EmilyE;Butler,JoshuaH;Haney,ReaganS;Merino,EmilioF;Butschek,GrantJ;Rizopoulos,Zaira;Totrov,Maxim;Cassera,MariaB;Carlier,PaulR
- 通讯作者:Carlier,PaulR
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Paul R Carlier其他文献
Paul R Carlier的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Paul R Carlier', 18)}}的其他基金
Optimization of antimalarials targeting multiple life stages of the parasite
针对寄生虫多个生命阶段的抗疟药物的优化
- 批准号:
10745610 - 财政年份:2021
- 资助金额:
$ 7.59万 - 项目类别:
Optimization of antimalarials targeting multiple life stages of the parasite
针对寄生虫多个生命阶段的抗疟药物的优化
- 批准号:
10298005 - 财政年份:2021
- 资助金额:
$ 7.59万 - 项目类别:
Optimization of antimalarials targeting multiple life stages of the parasite
针对寄生虫多个生命阶段的抗疟药物的优化
- 批准号:
10689033 - 财政年份:2021
- 资助金额:
$ 7.59万 - 项目类别:
Interrogating plasmodial endocytosis with mefloquine-based affinity probes
用基于甲氟喹的亲和探针检测疟原虫内吞作用
- 批准号:
10089405 - 财政年份:2020
- 资助金额:
$ 7.59万 - 项目类别:
MEDICINAL CHEMISTRY, CHEMICAL SYNTHESIS, AND MASS SPECTROMETRY
药物化学、化学合成和质谱分析
- 批准号:
8168768 - 财政年份:2010
- 资助金额:
$ 7.59万 - 项目类别:
MEDICINAL CHEMISTRY, CHEMICAL SYNTHESIS, AND MASS SPECTROMETRY
药物化学、化学合成和质谱分析
- 批准号:
7954019 - 财政年份:2009
- 资助金额:
$ 7.59万 - 项目类别:
Development of vector-specific, resistance-breaking insecticides to reduce malari
开发病媒特异性、突破耐药性的杀虫剂以减少疟疾
- 批准号:
8445236 - 财政年份:2009
- 资助金额:
$ 7.59万 - 项目类别:
Development of vector-specific, resistance-breaking insecticides to reduce malari
开发病媒特异性、突破耐药性的杀虫剂以减少疟疾
- 批准号:
8237040 - 财政年份:2009
- 资助金额:
$ 7.59万 - 项目类别:
Development of vector-specific, resistance-breaking insecticides to reduce malari
开发针对病媒的抗药性杀虫剂以减少疟疾
- 批准号:
7657602 - 财政年份:2009
- 资助金额:
$ 7.59万 - 项目类别:
Development of vector-specific, resistance-breaking insecticides to reduce malari
开发针对病媒的抗药性杀虫剂以减少疟疾
- 批准号:
7796794 - 财政年份:2009
- 资助金额:
$ 7.59万 - 项目类别:
相似海外基金
Molecular Simulations of Additive Self-Assembly, Rheology, and Surface Adsorption in Complex Fluids
复杂流体中添加剂自组装、流变学和表面吸附的分子模拟
- 批准号:
2901619 - 财政年份:2024
- 资助金额:
$ 7.59万 - 项目类别:
Studentship
An Adsorption-Compression Cold Thermal Energy Storage System (ACCESS)
吸附压缩冷热能存储系统(ACCESS)
- 批准号:
EP/W027593/2 - 财政年份:2024
- 资助金额:
$ 7.59万 - 项目类别:
Research Grant
Tuning Precision Fabricated Liquid Crystal Adsorbents - Toward Tailored Adsorption of Per- and Polyfluorinated Alkyl Substances
调整精密制造的液晶吸附剂 - 针对全氟和多氟烷基物质的定制吸附
- 批准号:
24K17729 - 财政年份:2024
- 资助金额:
$ 7.59万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Thermal stability of adsorption solar power plants
吸附式太阳能发电厂的热稳定性
- 批准号:
2871817 - 财政年份:2024
- 资助金额:
$ 7.59万 - 项目类别:
Studentship
Computational Studies of Gas Adsorption in Special Nuclear Materials (SNMs).
特殊核材料(SNM)中气体吸附的计算研究。
- 批准号:
2903366 - 财政年份:2024
- 资助金额:
$ 7.59万 - 项目类别:
Studentship
Metal tolerance and metal adsorption through phycosphere control
通过藻圈控制实现金属耐受性和金属吸附
- 批准号:
23H02303 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Collaborative Research: Integrated experiments and simulations to understand the mechanism and consequences of polymer adsorption in films and nanocomposites
合作研究:综合实验和模拟来了解薄膜和纳米复合材料中聚合物吸附的机制和后果
- 批准号:
2312325 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
Standard Grant
Investigation of adsorption of exosomes on porous materials and regulating the behavior to create separation, purification and preservation techniques
研究外泌体在多孔材料上的吸附并调节行为以创建分离、纯化和保存技术
- 批准号:
23KJ0192 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Super-Resolution Imaging of Surface Adsorption on Single Nanoparticles for Electrochemical Dechlorination
用于电化学脱氯的单个纳米颗粒表面吸附的超分辨率成像
- 批准号:
2303933 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
Standard Grant
Science for Boundary Lubrication - Essence of Low Friction Mechanism Based on Structure and Dynamics of Additive Adsorption Layer
边界润滑科学——基于添加剂吸附层结构和动力学的低摩擦机制本质
- 批准号:
23H05448 - 财政年份:2023
- 资助金额:
$ 7.59万 - 项目类别:
Grant-in-Aid for Scientific Research (S)